Stay in the know
We’ll send you the latest insights and briefings tailored to your needs
Subscribe now
Herbert Smith Freehills Kramer (HSF Kramer) is pleased to be advising CSL on its recently announced proposed demerger of its Seqirus business (Seqirus) as a standalone ASX-listed entity by the end of Financial Year 2026.
Seqirus is one of the world’s largest influenza vaccine providers, dedicated to advancing public health through innovative vaccine solutions and pandemic preparedness.
The HSF Kramer team is led by partners Priscilla Bryans, Baden Furphy, Alexander Mackinnon, and Michael Ziegelaar, with partner Ryan Leslie advising on the tax aspects of the transaction.
Key contacts
Priscilla Bryans
Partner, Melbourne
Baden Furphy
Partner, Melbourne
Alexander Mackinnon
Partner, Melbourne
Michael Ziegelaar
Partner, Melbourne
Ryan Leslie
Partner, Melbourne
Media contact
For further information on this news article, please contact:
Gina Baldassarre
External Communications Manager
Sydney
More news
12 六月 2026
Herbert Smith Freehills Kramer advises on the financing for GSK plc's US$10.6 billion acquisition of Nuvalent Inc.
Leading global law firm Herbert Smith Freehills Kramer has advised the arranging banks on the financing to support the proposed US$10.6 billion …
12 六月 2026
HSF Kramer partner Heike Schmitz appointed to German Government’s Sustainable Finance Advisory Board
Heike Schmitz, partner at Herbert Smith Freehills Kramer in Frankfurt and co-head of the firm’s ESG practice in EMEA, has been appointed to the German …
11 六月 2026
Herbert Smith Freehills Kramer conseille ALTEN dans le cadre de l’acquisition du groupe KLANIK
Herbert Smith Freehills Kramer a conseillé ALTEN, leader mondial de l’Ingénierie et des IT Services coté sur Euronext Paris, dans le cadre de …